Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Caspase Inhibition in Islet Transplantation

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2012 by University of Alberta
Sponsor:
Collaborator:
Conatus Pharmaceuticals Inc.
Information provided by (Responsible Party):
James Shapiro, University of Alberta
ClinicalTrials.gov Identifier:
NCT01653899
First received: July 12, 2012
Last updated: July 27, 2012
Last verified: July 2012

July 12, 2012
July 27, 2012
June 2012
June 2015   (final data collection date for primary outcome measure)
To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant [ Time Frame: 3 years post-initial transplant ] [ Designated as safety issue: Yes ]
The primary objective of this protocol is to assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant. A tracking log will document adverse events and unexpected complications associated with IDN-6556 using a grading classification as per protocol.
Same as current
Complete list of historical versions of study NCT01653899 on ClinicalTrials.gov Archive Site
  • 1. To determine the proportion of subjects treated with IDN-6556 who achieve and maintain insulin independence after the first or subsequent islet transplant. [ Time Frame: 3 years post-initial transplant ] [ Designated as safety issue: No ]
    The proportion of study participants achieving and maintaining insulin independence (c-peptide, HbA1c level) with good glycemic control (blood sugar measurement) at Day 90 and 1, 2, 3 years post-initial islet transplant.
  • 2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients. [ Time Frame: 3 years post-initial transplant ] [ Designated as safety issue: No ]
    Immune monitoring for HLA and panel reactive antibody will be performed using serum samples
Same as current
Not Provided
Not Provided
 
Caspase Inhibition in Islet Transplantation
Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556

This is an Investigator Initiated, Phase I/II study, where Type 1 diabetic participants will receive a 14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following their first islet transplant. Two pilot studies are proposed to establish the optimal safety and efficacy dose of IDN-6556 (25 mg or 100 mg twice daily). Participants of both pilot studies will receive islet cell transplants under the University of Alberta's standard-of-care therapy.

The primary objective of this protocol is to assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant.

Secondary objectives include:

  1. To determine the proportion of subjects treated with IDN-6556 who achieve and maintain insulin independence after the first or subsequent islet transplant.
  2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.
Not Provided
Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes
Drug: IDN-6556
14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 25 mg twice daily.
Other Name: Emricasan
Experimental: IDN-6556
Drug
Intervention: Drug: IDN-6556
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
12
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

To be eligible the participant must have had T1DM for more than 5 years, complicated by at least 1 of the following situations that persist despite intensive insulin management efforts:

  • Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels < 3.0 mmol/L, indicated by, 1 or more episodes of severe hypoglycemia requiring third party assistance within 12 months, a Clarke score ≥ 4, HYPO score ≥ 1,000, lability index (LI) ≥ 400 or combined Hypo/LI > 400/300
  • Metabolic instability, characterized by erratic blood glucose levels that interfere with daily activities and or 1 or more hospital visits for diabetic ketoacidosis over the last 12 months.

Participants must be capable of understanding the purpose and risks of the study and must sign a statement of informed consent.

Exclusion Criteria:

  1. Severe co-existing cardiac disease, characterized by any one of these conditions: (a) recent myocardial infarction (within past 6 months); (b) left ventricular ejection fraction < 30%; or (c) evidence of ischemia on functional cardiac exam.
  2. Active alcohol or substance abuse, to include cigarette smoking (must be abstinent for 6 months prior to transplant).
  3. Psychiatric disorder making the subject not a suitable candidate for transplantation, (e.g., schizophrenia, bipolar disorder, or major depression that is unstable or uncontrolled on current medication).
  4. History of non-adherence to prescribed regimens.
  5. Active infection including Hepatitis C, Hepatitis B, HIV, TB (subjects with a positive PPD performed within one year of enrollment, and no history of adequate chemoprophylaxis).
  6. Any history of or current malignancies except squamous or basal skin cancer.
  7. BMI > 35 kg/m2 at screening visit.
  8. Age less than 18 or greater than 68 years.
  9. Measured glomerular filtration rate (GFR) < 60 mL/min/1.73 m2.
  10. Presence or history of macroalbuminuria (> 300 mg/g creatinine).
  11. Clinical suspicion of nephritic (hematuria, active urinary sediment) or rapidly progressing renal impairment (e.g. Increase in serum creatinine of 25% within the last 3-6 months).
  12. Baseline Hb < 105g/L (< 10.5 g/dL) in women, or < 120 g/L (< 12 g/dL) in men.
  13. Baseline screening liver function tests outside of normal range, with the exception of uncomplicated Gilbert's Syndrome. An initial LFT panel with any values > 1.5 times the upper limit of normal (ULN) will exclude a patient without a re-test; a re test for any values between ULN and 1.5 times ULN should be made, and if the values remain elevated above normal limits, the patient will be excluded.
  14. Untreated proliferative retinopathy.
  15. Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding.
  16. Previous transplant or evidence of significant sensitization on PRA (at the discretion of the investigator).
  17. Insulin requirement > 1.0 U/kg/day
  18. HbA1C > 12%.
  19. Uncontrolled hyperlipidemia [fasting LDL cholesterol > 3.4 mmol/L (133 mg/dL), treated or untreated; and/or fasting triglycerides > 2.3 mmol/L (90 mg/dL)].
  20. Under treatment for a medical condition requiring chronic use of steroids.
  21. Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.5.
  22. Untreated Celiac disease.
  23. Patients with Graves disease will be excluded unless previously adequately treated with radioiodine ablative therapy.
Both
18 Years to 68 Years
No
Contact: Andrew Malcolm, MD PhD 780-407-6952 andrew.malcolm@ualberta.ca
Contact: Parastoo Dinyari, BSc 780-407-3904 parastoo@islet.ca
Canada
 
NCT01653899
Pro00024049
Yes
James Shapiro, University of Alberta
University of Alberta
Conatus Pharmaceuticals Inc.
Principal Investigator: A.M. James Shapiro, MD PhD University of Alberta
University of Alberta
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP